Olodaterol
- Generic Name
- Olodaterol
- Brand Names
- Inspiolto Respimat, Stiolto, Striverdi Respimat
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26N2O5
- CAS Number
- 868049-49-4
- Unique Ingredient Identifier
- VD2YSN1AFD
- Background
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel i...
- Indication
Olodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
- Associated Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- -
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT03240575
- Locations
- 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Cardiovascular Function in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT03055988
- Locations
- 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇩🇪Klinische Forschung Berlin GbR, Berlin, Germany
🇩🇪Praxis Dr. med. Claus Keller, Frankfurt, Germany
Drug Utilization Study for Olodaterol
- Conditions
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27606
- Registration Number
- NCT03030638
- Locations
- 🇫🇷
IMS Health Information solutions, Courbevoie, France
🇳🇱Pharmo Institute, Utrecht, Netherlands
🇩🇰Aarhus Universitetshospital Skejby, Aarhus, Denmark
Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02969317
- Locations
- 🇨🇳
West China Hospital, Chengdu, China
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 106
- Registration Number
- NCT02853123
- Locations
- 🇧🇪
Hasselt - PRAC Aumann, J-L, Hasselt, Belgium
🇨🇦McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇨🇦McMaster Univ. Medical Centre, Hamilton, Ontario, Canada
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 221
- Registration Number
- NCT02683109
- Locations
- 🇦🇹
Ordination Dr. Robert Voves, 8330 Feldbach, Feldbach, Austria
🇦🇹KH d. Elisabethinen Linz, Linz, Austria
🇩🇰Aarhus Universitetshospital, Aarhus, Denmark
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 184
- Registration Number
- NCT02629965
- Locations
- 🇯🇵
Tohno Chuo Clinic, Gifu, Mizunami, Japan
🇯🇵Kirigaoka Tsuda Hospital, Fukuoka, Kitakyushu, Japan
🇯🇵Nishi Fukuoka Hospital, Fukuoka, Fukuoka, Japan
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
- Conditions
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7903
- Registration Number
- NCT02296138
- Locations
- 🇺🇸
1237.19.10003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸1237.19.10021 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇨🇦1237.19.20021 Boehringer Ingelheim Investigational Site, Moncton, New Brunswick, Canada
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02030535
- Locations
- 🇩🇪
1237.7.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1237.7.49007 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇩🇪1237.7.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
- Conditions
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 809
- Registration Number
- NCT02006732
- Locations
- 🇺🇸
1237.26.10613 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸1237.26.10606 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇦🇺1237.26.61004 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.